Evidence map›Paper›PMID 40684391›Full record

ReviewCurrent oncology reports2025

The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?

Michele Maffezzoli, Ria Nagpal, Mohamed Elewaily, Lohitha Pedapati, Justin Samuel, Sebastiano Buti, Umberto Malapelle, Akash Maniam, Giuseppe Luigi Banna

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michele MaffezzoliDepartment of Medicine and Surgery, University of Parma, Parma, Italy. michele.maffezzoli@unipr.it.ORCID http://orcid.org/0000-0001-7877-8988
Ria NagpalPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Mohamed ElewailyPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Lohitha PedapatiPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Justin SamuelPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Sebastiano ButiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Umberto MalapelleDepartment of Public Health, University of Naples Federico II, Naples, Italy.
Akash ManiamPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.
Giuseppe Luigi BannaPortsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAdjuvant immunotherapy has improved outcomes in several cancers, although patient selection and toxicity remain challenges. Circulating tumor DNA (ctDNA) has emerged as a biomarker for minimal residual disease (MRD) detection, although its role in guiding adjuvant immunotherapy remains unproven. The aim of this review was to summarize the current evidence on ctDNA in the adjuvant immunotherapy setting of solid tumors. RECENT

findingsData from various tumor types guiding ctDNA-driven treatment escalation or de-escalation in the context of adjuvant immunotherapy remain sparse, limited to small prospective trials, many of which have struggled with enrolment and yielded inconclusive results. Challenges include analytical and clinical validation, as well as the optimal treatment management of either ctDNA positive and negative patients, posing ethical challenges in designing clinical trials. ctDNA has strong prognostic value in detecting MRD but is not validated for guiding adjuvant immunotherapy, and well-designed prospective trials are required to establish its role. Future research should focus on integrated models combining ctDNA with other biomarkers to improve sensitivity and specificity, while balancing cost-effectiveness and clinical feasibility.

Indexed as

Biomarkers, TumorCirculating Tumor DNAImmune Checkpoint InhibitorsNeoplasmsChemotherapy, AdjuvantHumansImmunotherapyNeoplasm, ResidualPrognosisBiomarkers, TumorCirculating Tumor DNAImmune Checkpoint InhibitorsAdjuvantCirculating tumor DNAImmune checkpoint inhibitorsImmunotherapyPredictivePrognostic

Identifiers

PMID40684391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.